Stratos Wealth Advisors’s TG Therapeutics TGTX Stock Holding History

Stratos Wealth Advisors’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$386K	Sell	7,022 -1,000	-12%	-$40.9K	0.02%	443
2026 Q1	$266K	Hold	8,022	–	–	0.02%	509
2025 Q4	$239K	Hold	8,022	–	–	0.01%	581
2025 Q3	$290K	Hold	8,022	–	–	0.01%	562
2025 Q2	$289K	Buy	8,022 +22	+0.3%	+$819	0.02%	551
2025 Q1	$315K	Hold	8,000	–	–	0.02%	539
2024 Q4	$241K	Buy	+8,000	New	+$230K	0.01%	630

Other funds holding TGTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Stratos Wealth Advisors's TGTX Position: Q2 2026 in Review

Stratos Wealth Advisors reduced its TG Therapeutics (TGTX) stake by 12% in Q2 2026, selling an estimated $40.9K and leaving 7,022 shares worth $386K. The position accounts for 0.02% of the portfolio, ranked #443.

Stratos Wealth Advisors first reported a position in TGTX in Q4 2024 and has held it in 7 quarters since. 429 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

Stratos Wealth Advisors held 7,022 shares of TG Therapeutics worth $386K as of Q2 2026.
Stratos Wealth Advisors sold 1,000 TG Therapeutics shares in Q2 2026, an estimated $40.9K.
TG Therapeutics made up 0.02% of Stratos Wealth Advisors's portfolio in Q2 2026, its #443 holding.
Stratos Wealth Advisors first reported a position in TG Therapeutics in Q4 2024 and has held it in 7 quarters since.
429 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on Stratos Wealth Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.